Malin
Executivos
Veja o organograma con seus 7 executivos principais
Biografias mais buscadas da Malin
- Jean-Michel Cosséry, Independent Non-Executive Director
- Rudy Mareel, Lead Independent Non-Executive Director
- Kirsten Drejer, Independent Non-Executive Director
Recentes movimentos de executivos em Malin
- Darragh Lyons, Chief Executive Officer and Director está prestes a deixar a empresa (Notícia publicada em 4 de agosto de 2023).
- Fiona Dunlevy atualmente Company Secretary, passará a Executive Director em 2 de out. de 2023 (Notícia publicada em 4 de agosto de 2023).
- Liam Daniel antes Non-Executive Chairman of the Board, agora é Chief Executive Officer (Notícia publicada em 4 de agosto de 2023).
Criar um alerta
para seguir os movimentos de executivos da Malin.
Pesquisa de Mercado
Malin possui 338 concorrentes concorrentes Afiniti (Estados Unidos), Alida (Reino Unido) e ABI Research (Estados Unidos).
Popular M&A news in Pesquisa de Mercado
- Sensor Tower adquiriu Data.ai (publicado em 22 de março de 2024).
- Accenture adquiriu GemSeek (publicado em 21 de fevereiro de 2024).
- O novo nome de Sago é Sago. (publicado em 10 de abril de 2023).
Outros contatos sugeridos na indústria do Pesquisa de Mercado
Notícias
Últimos comunicados de imprensa de Malin
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology | Poseida Therapeutics, Inc.
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology : Malin PLC
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma | Poseida Therapeutics, Inc.
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma : Malin PLC
- Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma | Poseida Therapeutics, Inc.
- Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 : Malin PLC
- Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma : Malin PLC
- Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 | Poseida Therapeutics, Inc.
- CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer : Malin PLC
- View more press releases Close
Redes sociais sobre Malin
- Malin na Wikipedia, Google News e Yahoo Finance
- Malin na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Kirsten Drejer 
Ligue para a Malin em +353 ...
